Sandoz, the global leader in generic and biosimilar medicines, is poised to enhance its ophthalmology franchise with the signing of an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, Inc. 

The deal, valued at an upfront cash purchase payment of USD 170 million, includes a biologics license application, product inventory, ophthalmology sales, field reimbursement talent, and access to proprietary commercial software.

Keren Haruvi, President Sandoz North America, expressed enthusiasm, stating, "I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI® reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US."

The acquisition aligns with Sandoz's dedication to providing expanded treatment options for US patients dealing with vision impairment and loss. By incorporating the CIMERLI® business from Coherus, Sandoz aims to build a robust ophthalmic platform that supports future product launches.

The closing of the acquisition is anticipated in the first half of 2024, subject to standard conditions and approvals. This strategic move reflects Sandoz's commitment to advancing its biosimilar portfolio and contributing to improved access to essential medicines in the United States.